| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 02 Oct 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2025 | Download |
| 04 Jul 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2025 | Download |
| 03 Jul 2025 | Other relevant information | The Company informs about the dividends payment. | Download |
| 18 Jun 2025 | Announcement of general shareholders’ meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. | Download |
| 08 May 2025 | On business and financial situation | The Company releases the press release related to the first three months of 2025 financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2013 | Información sobre resultados (2) | Download | |
| 21 Feb 2013 | Información sobre resultados | Download | |
| 21 Feb 2013 | Informe Anual de Gobierno Corporativo 2012 | Download | |
| 08 Nov 2012 | Información financiera intermedia | Download | |
| 08 Nov 2012 | Información sobre resultados | Download |